Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutations targeting the coagulation pathway are enriched in brain metastases.
Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, Sciandivasci A, Munzone E, DiMeco F, Pelicci PG, Riva L, Pelicci G. Richichi C, et al. Among authors: sciandivasci a. Sci Rep. 2017 Jul 26;7(1):6573. doi: 10.1038/s41598-017-06811-x. Sci Rep. 2017. PMID: 28747664 Free PMC article.
Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach.
Munzone E, Casali C, Aurilio G, Botteri E, Perin A, Pelicci G, Brescia P, Sciandivasci A, Adamoli L, Viale G, Dimeco F. Munzone E, et al. Among authors: sciandivasci a. Ecancermedicalscience. 2013 Apr 18;7:309. doi: 10.3332/ecancer.2013.309. Print 2013. Ecancermedicalscience. 2013. PMID: 23634179 Free PMC article.
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Aurilio G, et al. Among authors: sciandivasci a. Acta Oncol. 2013 Nov;52(8):1649-56. doi: 10.3109/0284186X.2012.754990. Epub 2013 Jan 17. Acta Oncol. 2013. PMID: 23327413
Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases.
Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolé F. Munzone E, et al. Among authors: sciandivasci a. Ann Oncol. 2012 Nov;23(11):2884-2890. doi: 10.1093/annonc/mds098. Epub 2012 Apr 29. Ann Oncol. 2012. PMID: 22547541 Free article.
Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases.
Botteri E, Munzone E, Intra M, Bagnardi V, Rotmensz N, Bazolli B, Montanari B, Aurilio G, Sciandivasci A, Esposito A, Pagani G, Adamoli L, Viale G, Nolè F, Goldhirsch A. Botteri E, et al. Among authors: sciandivasci a. Breast Cancer Res Treat. 2013 Feb;138(1):303-10. doi: 10.1007/s10549-013-2449-6. Epub 2013 Feb 15. Breast Cancer Res Treat. 2013. PMID: 23412771
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. Aurilio G, et al. Among authors: sciandivasci a. Eur J Cancer. 2014 Jan;50(2):277-89. doi: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21. Eur J Cancer. 2014. PMID: 24269135 Free article.
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, Pruneri G, Intra M, Sciandivasci A, Gentilini O, Luini A, Viale G, Veronesi P, Colleoni M. Munzone E, et al. Among authors: sciandivasci a. Breast Cancer Res Treat. 2014 Aug;146(3):573-82. doi: 10.1007/s10549-014-3043-2. Epub 2014 Jul 10. Breast Cancer Res Treat. 2014. PMID: 25007961
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: sciandivasci a. Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26. Cancer Lett. 2017. PMID: 28131905 Clinical Trial.
20 results